<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cardinal Health Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/cardinal-health-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABC) AmerisourceBergen Posts Modest Second Quarter Results</title>
		<link>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760</link>
		<comments>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99760</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) posted second quarter fiscal 2012 earnings of 81 cents per share, in line with the Zacks Consensus Estimate. However, earnings increased 5.2% from the year-ago period, spurred by higher revenues and a lower share count. Revenues Total revenue for the second quarter edged up 1.6% to $20.1 billion, which were also in line with the Zacks Consensus Estimate. The modest advance in revenues was the result of a 6% increase in AmerisourceBergen Specialty Group’s revenue. The revenue increase for the AmerisourceBergen Specialty Group segment was driven by growth in third party logistics and vaccine and physician office distribution business. The robust performance of AmerisourceBergen Drug Corporation’s institutional segment was offset by the loss of a significant retail customer. TheraCom, a recent acquisition, also contributed toward the quarter’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134</link>
		<comments>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88134</guid>
		<description><![CDATA[We reiterate our Outperform rating on Cardinal Health (CAH). Its first-quarter fiscal 2012 (ended September 30) adjusted earnings per share of 73 cents beat the Zacks Consensus Estimate of 72 cents. Earnings from continuing operations (as reported) dropped about 19% year over year reflecting a previous-year gain from the sale of CareFusion (CFN) shares. Sales for the first quarter rose 10% year over year to $26.8 billion, exceeding the Zacks Consensus Estimate of $26.3 billion. Sales were boosted by growth across the board, notably, buoyancy in the larger Pharmaceutical segment. Revenues from the Pharmaceutical segment spiked 10% year over year in the quarter. Acquisitions contributed to growth as did organic growth from pre-existing clients. Sales from the smaller Medical segment climbed 10%, driven by higher sales to existing and net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102</link>
		<comments>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:57:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86102</guid>
		<description><![CDATA[Omnicell Inc. (OMCL) reported EPS of 9 cents during the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate of 8 cents and the year-ago quarter EPS of 4 cents. Reported earnings shot up 125% on a year-over-year basis primarily due to the reduction in effective tax rate from 60% in the year-ago quarter to 35% in the reported quarter. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. Product revenue, contributing 77.3% of revenues, increased 15.0% to $49.7 million in the quarter while the same from Services and Others (contributing the rest), witnessed an upside of 12.3%. Cost of Product sales were up 13.6% to $22.4 million in the quarter. However, cost of Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764</link>
		<comments>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764#comments</comments>
		<pubDate>Fri, 07 Oct 2011 16:27:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84764</guid>
		<description><![CDATA[We recently upgraded our rating on Cardinal Health, Inc. (CAH) to Outperform. Earnings for the fourth quarter narrowly beat the Zacks Consensus Estimate. Cardinal&#8217;s size and diversity partly insulate it from economic cycles, and its generics business continues to grow at a healthy pace. Moreover, Cardinal&#8217;s Pharmaceutical and Medical segments have revamped operations. The company continues to nurture its specialty platforms and engage in periodic tuck-in acquisitions. Although client and supplier concentration and reliance on group purchasing organizations remain areas of concern, the same is partly mitigated through long-term contracts. While margins are thin in the bulk Pharma business, the business mix is evolving in favor of the non-bulk segment. Robust cash flow, high cash balance and revolving credit facility bestow liquidity for share repurchase and acquisitions. CARDINAL HEALTH (CAH): ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/07/cah-cardinal-health-incorporated-bull-of-the-day-2/84764/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282</link>
		<comments>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282#comments</comments>
		<pubDate>Mon, 03 Oct 2011 19:20:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84282</guid>
		<description><![CDATA[We upgrade our rating on Cardinal Health, Inc. (CAH) to Outperform. Earnings for the fourth quarter narrowly beat the Zacks Consensus Estimate. Cardinal&#8217;s size and diversity partly insulate it from economic cycles. Its generics business continues to grow at a healthy pace. Moreover, Cardinal&#8217;s Pharmaceutical and Medical segments have revamped operations. The company continues to nurture its specialty platforms and engage in periodic tuck-in acquisitions. Although client and supplier concentration and reliance on group purchasing organizations remain areas of concern, the same is partly mitigated through long-term contracts. While margins are thin in the bulk Pharma business, the business mix is evolving in favor of the non-bulk segment. Robust cash flow, high cash balance and revolving credit facility bestow liquidity for share repurchase and acquisitions. CARDINAL HEALTH (CAH): Free Stock ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/03/cah-cardinal-health-incorporated-bull-of-the-day/84282/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310</link>
		<comments>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:17:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83310</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $16.00. Omnicell reported an adjusted EPS of 8 cents in the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate and the year-ago quarter’s EPS of 6 cents. Total revenue for the second quarter was $61.0 million, up 6.6% year over year and surpassed the Zacks Consensus Estimate of $60.0 million. Product revenue, contributing 75.8% of Omnicell’s top line, increased 8.5% to $46.2 million in the quarter while revenues from Services and Others (contributing the rest), witnessed a marginal upside of 1.4%. The company operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAG) Walgreen in Elite League</title>
		<link>http://www.stockbloghub.com/2011/09/20/wag-walgreen-in-elite-league/83351</link>
		<comments>http://www.stockbloghub.com/2011/09/20/wag-walgreen-in-elite-league/83351#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Catalyst Health Solutions Inc]]></category>
		<category><![CDATA[CHSI]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83351</guid>
		<description><![CDATA[Recently, Walgreen (WAG) was ranked 29th among the top 30 technology innovators in the U.S, according to the 2011 Information Week 500. The company added another feather in its cap when it became the top-ranked company in the retail and general merchandising category. The company considers both the achievements as huge recognition for its innovative technology in healthcare industry given the company secured a place in the top 30 list (in 2010 it was ranked 153 and secured the 3rd position among retail and general merchandising). Walgreen’s IT division is presently developing Walgreens 2.0, which will likely enhance its technology infrastructure across multiple platforms, including its network of more than 7,700 stores. Walgreen has been impacted over the past few quarters by high unemployment levels and lower discretionary spending. Moreover, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/wag-walgreen-in-elite-league/83351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WAG) Walgreen Ranked as Technology Innovator</title>
		<link>http://www.stockbloghub.com/2011/09/15/wag-walgreen-ranked-as-technology-innovator/83270</link>
		<comments>http://www.stockbloghub.com/2011/09/15/wag-walgreen-ranked-as-technology-innovator/83270#comments</comments>
		<pubDate>Thu, 15 Sep 2011 18:08:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Catalyst Health Solutions Inc]]></category>
		<category><![CDATA[CHSI]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83270</guid>
		<description><![CDATA[Recently, Walgreen (WAG) was ranked 29th among the top 30 technology innovators in the U.S, according to the 2011 InformationWeek 500. The company added another feather in its cap when it became the top-ranked company in the retail and general merchandising category. The company considers both the achievements as huge recognition for its innovative technology in healthcare industry given the company secured a place in the top 30 list (in 2010 it was ranked 153 and secured the 3rd position among retail and general merchandising). Walgreen’s IT division is presently developing Walgreens 2.0, which will likely enhance its technology infrastructure across multiple platforms, including its network of more than 7,700 stores. Walgreen has been impacted over the past few quarters by high unemployment levels and lower discretionary spending. Moreover, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/wag-walgreen-ranked-as-technology-innovator/83270/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113</link>
		<comments>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:29:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82113</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue to benefit from growth in the pharmaceutical industry, which is driven by several factors like aging population, increased use of generics, introduction of new treatments, increased use of drug therapies and favorable legislative developments. The aforesaid points are continually helping the company, which increased its 2011 earnings guidance range following the release of the third quarter fiscal 2011 financial results. AmerisourceBergen now expects 2011 earnings to lie in the range of $2.52 &#8211; $2.56 per share (previous guidance: $2.41 &#8211; $2.49). We expect fiscal 2011 earnings to increase almost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s Electronic Health Record Wins Certification</title>
		<link>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065</link>
		<comments>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:01:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77065</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL), a leading developer and marketer of end-to-end automation solutions for the medication-use process, recently announced that its newly launched G4 platform received the ONC-ATCB certification as a Modular Electronic Health Record (“EHR&#8221;). Omnicell became the first hospital pharmacy automation company to achieve this certification and the company intends to support its clients to qualify for federal funding incentives under the American Recovery and Reinvestment Act (“ARRA”). The Centers for Medicare &#38; Medicaid Services, on May 19, 2011, made the first round of payments totaling $75 million to providers who successfully fulfilled the Stage One requirements for Meaningful Use.  The fulfillment of Meaningful Use criteria is essential for securing federal incentives. EHR automates the process of writing prescriptions and enables the physicians to send prescriptions directly to a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell  Earns Second Consecutive Best in Klas Award</title>
		<link>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681</link>
		<comments>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:33:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76681</guid>
		<description><![CDATA[Omnicell (OMCL), recently announced that it has received recognition for its OmniRx automated dispensing system from leading research firm, KLAS for the second consecutive year.  Along with the  2011 “Best in KLAS&#8221; award for Automated Medication Dispensing Units for large hospitals with more than 200 beds category, Omnicell was also  recognized  as the Category Leader for OmniRx for hospitals under 200 beds. This is the sixth consecutive year that OmniRx has received this KLAS ranking as Category Leader. Omnicell, for the second consecutive year, was adjudged Category Leader for Pharmacy Automation: Medication Carousels for its WorkflowRx Carousel and Category Leader in the new Anesthesia Cabinets award category for Omnicell&#8217;s Anesthesia Workstation. Moreover, Omnicell&#8217;s OmniLinkRx received the Category Leader Distinction for Medication Order Management Systems in Klas’ Software &#38; Professional Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Third Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565</link>
		<comments>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72565</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report its third-quarter fiscal 2011 (ending March) results on Thursday, April 28. The company expects earnings per share in the range of $2.54 to $2.60 for fiscal 2011. The current Zacks Consensus Estimate for revenues and earnings for the third quarter are $25.6 billion and 69 cents per share, respectively. Second Quarter Recap Cardinal Health reported second-quarter fiscal 2011 adjusted earnings per share of 69 cents, beating the Zacks Consensus Estimate of 61 cents and surpassing the year-ago results of 57 cents. Total sales were up 2% year over year to $25.4 billion, beating the Zacks Consensus Estimate. Higher sales from the core Pharmaceutical division were partly offset by a modest decline in the Medical segment. Revenues from the larger Pharmaceutical segment moved up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Enters Agreement with Masimo</title>
		<link>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535</link>
		<comments>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:12:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20535</guid>
		<description><![CDATA[CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

